Skip to main content

SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD
9.88 -0.44 (-4.26%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap448.66M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out45.41M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume442,784
Open10.26
Previous Close10.32
Day's Range9.06 - 10.37
52-Week Range7.30 - 12.90
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing immunotherapies leveraging human polyclonal antibodies. The company applies advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce human antibodies targeted at specific diseases, including infectious diseases, such as COVID-19 and influenza; immune system disorders, including type 1 diabetes and organ transplantation; and cancer. Its DiversitAb platform is applicable to a range of serious unmet needs in hum...

IndustryBiotechnology
Founded2014
Employees143
Stock ExchangeNASDAQ
Ticker SymbolSABS
Full Company Profile

Financial Performance

Financial Statements

News

SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study

SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza. SAB-176 is a quadrivalent fully human p...

3 days ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS

New York, New York--(Newsfile Corp. - November 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of SAB Biotherapeutics, Inc. ("SAB" or the "Company") (NASDAQ: SABS). Such investo...

5 days ago - Newsfile Corp

SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update

Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis

1 week ago - GlobeNewsWire

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Completed Business Combination with Big Cypress Acquisition Corp.

1 month ago - GlobeNewsWire

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, toda...

1 month ago - PRNewsWire

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

1 month ago - Business Wire

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of CO...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-p...

2 months ago - Business Wire

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-p...

2 months ago - Business Wire

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #ACTG--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...

2 months ago - Business Wire

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Bioth...

MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, toda...

2 months ago - PRNewsWire

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-p...

2 months ago - Business Wire

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Se...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...

2 months ago - Business Wire

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...

2 months ago - Business Wire

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-po...

3 months ago - Business Wire

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics

MIAMI, July 15, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today reported that Eddie J. Sulliva...

4 months ago - PRNewsWire

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-hum...

4 months ago - Business Wire

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-...

SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #COVID19--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high...

4 months ago - Business Wire

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Bus...

MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential subm...

4 months ago - PRNewsWire

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-hum...

5 months ago - Business Wire

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antib...

SIOUX FALLS, S.D. & MIAMI--(BUSINESS WIRE)-- #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-...

5 months ago - Business Wire

Big Cypress Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise...

MIAMI, FL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today that it closed its initial public offering of 11,500,000 units, which includes the full exercis...

10 months ago - GlobeNewsWire

Big Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

MIAMI, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. T...

10 months ago - GlobeNewsWire

Life sciences SPAC Big Cypress Acquisition raises deal size by 33% ahead of $100 million IPO

Big Cypress Acquisition, a blank check company targeting life science businesses in the US and Israel, raised the proposed deal size for its upcoming IPO on Monday. The Miami Beach, FL-based company now...

10 months ago - NASDAQ

Life sciences SPAC Big Cypress Acquisition files for a $75 million IPO

Big Cypress Acquisition, a blank check company targeting life science businesses in the US and Israel, filed on Monday with the SEC to raise up to $75 million in an initial public offering.

11 months ago - NASDAQ

Big Cypress Acquisition IPO Registration Document (S-1)

Big Cypress Acquisition Corp. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

11 months ago - SEC